Synthesis and antimycobacterial activity of azetidine-, quinazoline-, and triazolo-thiadiazole-containing pyrazines

Article abstract of DOI:10.1002/ardp.200900165

The re-emergence of tuberculosis (TB) as a global health problem over the past few decades, accompanied by the rise of drug-resistant strains of Mycobacterium tuberculosis, emphasizes the need for the discovery of new therapeutic drugs against this disease. The emerging serious problem both in terms of TB control and clinical management prompted us to synthesize a novel series of N-[2-(substituted aryl)-3-chloro-4-oxoazetidin-1-yl]-2-(pyrazin-2- yloxy)acetamide, 6-(substituted aryl)-3-[(pyrazin-2-yloxy)methyl][1,2,4] triazolo[3,4-b][1,3,4]thiadiazole, and N-[6-({2-[(pyrazin-2-yloxy)acetyl] hydrazino}sulfonyl)-2-methyl-4-oxo-1,4-dihydroquinazolin-3(2H)yl]-substituted aryl sulfonamides. The compounds were synthesized using the appropriate synthetic route. All synthesized compounds were assayed in vitro for antimycobacterial activity against the H37 Rv strain of Mycobacterium tuberculosis. The minimum inhibitory concentration (MIC) was determined for the test compounds as well as for the reference standards. The compound which exhibited good antimycobacterial activity contains the substituents fluorine and methoxy. These electron-withdrawing or -donating substituents amend the lipophilicity of the test compounds which, in turn, alter the permeability across the bacterial cell membrane. Compounds 28, 37, and 43 showed good antimycobacterial activity while compound 51 showed a promising antimycobacterial activity.

Full text of DOI:10.1002/ardp.200900165

228
Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Full Paper
Synthesis and Antimycobacterial Activity of Azetidine-,
Quinazoline-, and Triazolo-thiadiazole-containing Pyrazines
Chandrakant G. Bonde1, Ashok Peepliwal1, Naresh J. Gaikwad2
1 School of Pharmacy and Technology Management (Shirpur Campus), NMiMS University, Shirpur (M.S.),
India
2 Department of Pharmaceutical Sciences, Nagpur University Campus, Nagpur University, Nagpur, India.
The re-emergence of tuberculosis (TB) as a global health problem over the past few decades,
accompanied by the rise of drug-resistant strains of Mycobacterium tuberculosis, emphasizes the
need for the discovery of new therapeutic drugs against this disease. The emerging serious prob-
lem both in terms of TB control and clinical management prompted us to synthesize a novel
series of N-[2-(substituted aryl)-3-chloro-4-oxoazetidin-1-yl]-2-(pyrazin-2-yloxy)acetamide, 6-(substi-
tuted aryl)-3-[(pyrazin-2-yloxy)methyl][1,2,4]triazolo[3,4-b][1,3,4]thiadiazole, and N-[6-({2-[(pyrazin-
2-yloxy)acetyl]
hydrazino}sulfonyl)-2-methyl-4-oxo-1,4-dihydroquinazolin-3(2H)yl]-substituted
aryl sulfonamides. The compounds were synthesized using the appropriate synthetic route. All
synthesized compounds were assayed in vitro for antimycobacterial activity against the H37 Rv
strain of Mycobacterium tuberculosis. The minimum inhibitory concentration (MIC) was deter-
mined for the test compounds as well as for the reference standards. The compound which
exhibited good antimycobacterial activity contains the substituents fluorine and methoxy.
These electron-withdrawing or -donating substituents amend the lipophilicity of the test com-
pounds which, in turn, alter the permeability across the bacterial cell membrane. Compounds
28, 37, and 43 showed good antimycobacterial activity while compound 51 showed a promising
antimycobacterial activity.
Keywords: Antimycobacterial activity / Azetidine / Pyrazine / Quinazoline / Triazothiadiazole /
Received: July 16, 2009; accepted: September 27, 2009
DOI 10.1002/ardp.200900165
at which TB spreads in underdeveloped countries. There
Introduction
is also an alarming increase in cases of TB caused by mul-
tidrug-resistant strains of Mycobacterium tuberculosis, due,
in part, to inadequate drug therapy as a result of incor-
rectly selected medications or suboptimal drug dosing
[3].
Despite the undoubted success of widespread imple-
mentation of the DOTS (directly observed therapy, short-
course) strategy, only 70% of the world population is get-
ting the benefit of the same. Tuberculosis is a key driver
of the increase in synergy with the HIV epidemic, which
is having a devastating impact in some parts of the world
such as the WHO African Region, where 31% of new TB
cases are attributable to HIV co-infection [4]. Further-
more, the emergence of strains of Mycobacterium tubercu-
losis resistant to all the first-line drugs is causing serious
concern in some countries [5]. No new classes of drugs for
Tuberculosis (TB) is the disease caused by Mycobacterium
tuberculosis. Approximately two billion people are
infected world-wide. The World Health Organization esti-
mates that about two million people die every year from
TB due to the lack of an inability to afford proper health
care [1]. Overcrowding and ill-nourishment of poor peo-
ple living in large cities leads to a high incidence of the
disease due to the ease at which the infection can be
transferred [2]. This contributes to the accelerated speed
Correspondence: Chandrakant G. Bonde, School of Pharmacy and
Technology Management (Shirpur Campus), NMiMS University, Mumbai
Agra Road, At the Bank of Tapi River, Dist-Dhule, Shirpur (M.S.) 425405,
India.
E-mail: chandubonde@yahoo.co.in
Fax: +91 2563 286-552
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Activities of Substituted Pyrazine-Containing Analogues
229
A = 2-(Acetylamino)-5-(chlorosulfonyl) benzoic acid.
Scheme 1. Synthesis of compounds 2–63.
TB have been developed in the past 30 years, reflecting [(pyrazin-2-yloxy)methyl][1,2,4]triazolo[3,4-b][1,3,4]thiadi-
the inherent difficulties in discovery and clinical testing azole 42–51, and N-[6-({2-[(pyrazin-2-yloxy)acetyl]hydrazi-
of new agents and the lack of pharmaceutical industry no}sulfonyl)-2-methyl-4-oxo-1,4-dihydroquinazolin-3(2H)-
research in the area [6].
yl]-substituted aryl sulfonamide 54–63, with the aim of
Literature survey revealed that the pyrazine ring is obtaining new broad-spectrum antimycobacterial agents
important for antimycobacterial activity [7]. In addition, with less toxicity.
many azetidine, quinazoline, and triazolo-thiadiazole
In the present investigation, different derivatives of N-
derivatives exhibit a wide variety of biological activities [2-(substituted aryl)-3-chloro-4-oxoazetidin-1-yl]-2-(pyra-
such as antimicrobial [8], anti-inflammatory [9], antihis- zin-2-yloxy) acetamide 21–39, 6-(substituted aryl)-3-[(pyra-
taminic [10], antihypertensive [11], hypnotic [12], anti- zin-2-yloxy)methyl][1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
convulsant [13], etc. In view of the fact that the pyrazine 42–51, and N-[6-({2-[(pyrazin-2-yloxy)acetyl]hydrazino}-
ring possesses antimycobacterial activity, and as a part of sulfonyl)-2-methyl-4-oxo-1,4-dihydroquinazolin-3(2H)-yl]-
our ongoing studies in the area of antibacterial and anti- substituted aryl sulfonamide 54–63 were synthesized
mycobacterial agents [14, 15], we have synthesized some (Scheme 1) and evaluated for their antimycobacterial
novel N-[2-(substituted aryl)-3-chloro-4-oxoazetidin-1-yl]-2- activity.
(pyrazin-2-yloxy) acetamides 21–39, 6-(substituted aryl)-3-
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

230
C. G. Bonde et al.
Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Table 1. Physical and analytical data of compounds 2–20.
Table 2. Physical and analytical data of compounds 21–39
.
Compound
R
Molecular
formula
M.p.
(8C)
Yield
(%)
Compound
R
Molecular
formula
M.p.
(8C)
Yield
(%)
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
2,4-Dichloro
2,6-Dichloro
2-Chloro
2-Fluoro
4-Bromo-2-nitro
2-Nitro
2-Methoxy
3,4,5-Trimethoxy C18H19ClN4O6
3,5-Dimethoxy
3-Chloro
3-Fluoro
C15H11Cl3N4O3
C15H11Cl3N4O3
C15H12Cl2N4O3
C15H12ClFN4O3
C15H11BrClN5O5 218–219
C15H12ClN5O5
C16H15ClN4O4
169–170
172–173
185–186
212–213
56
54
46
59
61
52
49
45
62
53
57
52
59
46
48
59
42
45
41
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
2,4-Dichloro
2,6-Dichloro
2-Chloro
2-Fluoro
4-Bromo-2-nitro
2-Nitro
2-Methoxy
3,4,5-Trimethoxy C16H18N4O5
3,5-Dimethoxy
3-Chloro
3-Fluoro
C13H10Cl2N4O2
C13H10Cl2N4O2
C13H11ClN4O2
C13H11FN4O2
C13H10BrN5O4
C13H11N5O4
224–225
178–179
209–210
196–197
173–174
217–218
165–166
143–144
152–153
182–183
137–138
153–154
162–163
143–144
184–185
202–203
168–169
190–191
171–172
71
68
65
72
64
52
59
58
46
65
63
64
78
53
64
58
62
55
63
156–157
195–196
201–202
221–222
182–183
245–246
275–276
164–165
C17H17ClN4O5
C15H12Cl2N4O3
C15H12ClFN4O3
C15H12ClN5O5
C16H15ClN4O4
C14H14N4O3
C15H16N4O4
C13H11ClN4O2
C13H11FN4O2
C13H11N5O4
C14H14N4O3
C13H11BrN4O2
C14H14N4O2
C13H11ClN4O2
C13H11FN4O2
C13H11N5O4
C14H14N4O3
3-Nitro
3-Methoxy
4-Bromo
4-Methyl
4-Chloro
4-Fluoro
C15H12BrClN4O3 235–236
3-Nitro
C16H15ClN4O3
C15H12Cl2N4O3
C15H12ClFN4O3
C15H12ClN5O5
C16H15ClN4O4
191–192
227–228
235–236
212–213
238–239
3-Methoxy
4-Bromo
4-Methyl
4-Chloro
4-Fluoro
4-Nitro
4-Methoxy
4-Nitro
4-Methoxy
presence of TEA results in the formation of N-[2-(substi-
tuted aryl)-3-chloro-4-oxoazetidin-1-yl]-2-(pyrazin-2-yloxy)
acetamides 21–39. The structure was confirmed by ele-
mental analyses and spectral data (Table 2). Due to the
formation of the azetidine ring, the characteristic peaks
in the IR spectra were observed at 1720–1740 cm– 1 attrib-
uted to the monocyclic carbonyl group and the absence
of a peak at 1660–1680 cm– 1. In the1H-NMR, the cyclized
compounds showed the absence of a signal at d = 2.1–2.3
ppm for azomethane, which appeared as b-lactum pro-
ton as a duplet at d = 2.2–2.4 ppm integrating for one pro-
ton. In the FAB-MS spectra, the molecular ion peak [M+],
which appeared with different intensities, confirmed the
molecular weight of the compounds. An appearance of
the isotopic peak [M+ + 2] along with the molecular ion
peak confirmed the presence of a halogen atom in the
compounds.
2-(Pyrazin-2-yloxy)acetohydrazide 1 on treatment with
carbon disulphide and potassium hydroxide gives the
potassium salt of 2-[(pyrazin-2-yloxy)acetyl] hydrazine
carbodithioic acid. Compound 40 was cyclized with
hydrazine hydrate to get 4-amino-5-[(pyrazin-2-yloxy)-
methyl]-4H-1,2,4-triazole-3-thiol 41, which was treated
with various aromatic carboxylic acids in the presence of
phosphorous oxychloride to yield 6-(substituted aryl)-3-
[(pyrazin-2-yloxy)methyl][1,2,4]triazolo[3,4-b][1,3,4]thiadi-
Results and discussion
In the present investigation, different derivatives of N-[2-
(substituted aryl)-3-chloro-4-oxoazetidin-1-yl]-2-(pyrazin-2-
yloxy) acetamide 21–39, 6-(substituted aryl)-3-[(pyrazin-2-
yloxy)methyl][1,2,4]triazolo[3,4-b][1,3,4] thiadiazole 42–
51, and N-[6-({2-[(pyrazin-2-yloxy)acetyl]hydrazino}sul-
fonyl)-2-methyl-4-oxo-1,4-dihydroquinazolin-3(2H)-yl]-sub-
stituted aryl sulfonamide 54–63 were synthesized and
evaluated for their physical, analytica,l and spectral data.
Chemistry
To a solution of 2-(pyrazin-2-yloxy)acetohydrazide 1 in
ethanol, sodium acetate and various aromatic aldehydes
were added. This mixture was refluxed for 12 h. Excess
solvent was removed under vacuum to get compounds
2–20. The structures of compounds 2–20 were con-
firmed on the basis of elemental analyses and spectral
data (Table 1). The IR spectra showed NH-stretching bands
at 3215–3230 cm– 1 and the disappearance of NH2-
stretching bands at 3200–3400 cm– 1. In the 1H-NMR spec-
trum, the azomethane proton appeared as a multiplet at
d = 2.1–2.3 ppm integrating for one proton. Cyclization
of compounds 2–20 with chloroacetyl chloride in the
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Activities of Substituted Pyrazine-Containing Analogues
231
Table 3. Physical and analytical data of compounds 42–51.
Table 4. Physical and analytical data of compounds 54–63.
Compound
R
Molecular
formula
M.p.
(8C)
Yield
(%)
Compound
R
Molecular
formula
M.p.
(8C)
Yield
(%)
42
43
44
45
46
47
48
49
50
4-Chlorophenyl
4-Fluorophenyl
4-Bromophenyl
3,5-Dinitrophenyl C14H8N8O5S
4-Methyl phenyl
Phenyl
C14H9ClN6OS
C14H9FN6OS
C14H9BrN6OS
189–190
165–167
209–210
156–157
196–197
215–216
276–277
168–169
145–146
56
57
65
53
64
51
68
41
56
54
55
56
57
58
59
60
61
62
63
–
C20H20N8O7S2
C20H19ClN8O7S2 192–192
C20H19N9O9S2
C20H20N8O8S2
C21H22N8O8S2
C22H24N8O9S2
C20H18Cl2N8O7S2 278–279
C20H19FN8O7S2
C21H22N8O7S2
214–215
52
59
61
53
57
41
46
42
65
63
4-Chloro
3-Nitro
245–246
236–237
199–200
260–261
4-Hydroxy
4-Methoxy
3,5-Dimethoxy
2,4-Dichloro
4-Fluoro
C15H12N6OS
C14H10N6OS
C15H12N6OS
C12H8N6O2S
C16H14N6O3S
Benzyl
2-Furanyl
3,5-Dimethoxy
phenyl
245–246
231–232
4-Methyl
2-Nitro-4-chloro
C20H18ClN9O9S2 224–225
51
3-Pyridinyl
C13H9N7OS
191–192
49
azoles 42–51. Their structures were confirmed using ele-
mental and spectral analyses (Table 3). The IR absorption
peaks of 41 at 3167, 3270, and 2578 cm– 1 were assigned
to NH2- and SH-groups. When 41 was converted to 42–51,
the SH-peak disappeared and the new characteristic peak
of C-S-C appeared at 690 cm– 1. The evident change in the
1H-NMR spectrum of 40 after cyclization is that the sig-
nals of the amino and mercapto proton are at d = 5.81
and 13.39 ppm, respectively. The chemical shifts of the
triazole methyl group are seen in the range d = 2.30 to
2.51 ppm.
NH of SO2NH, which is absent in compound 53. In com-
pounds 54–63, the NH2 proton of compound 53 at d =
3.13 ppm was absent. These observations confirmed that
the reaction is complete. In the FABMS spectra, the
molecular ion peak [M+], which appeared at different
intensities, confirmed the molecular weight of the com-
pounds. An appearance of the isotopic peak [M+ + 2] along
with the molecular ion peak confirmed the presence of a
halogen atom in the compounds.
2-(Acetylamino)-5-(chlorosulfonyl) benzoic acid was
condensed with 2-(pyrazin-2-yloxy)acetohydrazide 1 to
yield 2-(acetylamino)-5-({2-[(pyrazin-2-yloxy)acetyl] hydra-
zino}sulfonyl)benzoic acid 52, which was then reacted
with hydrazine hydrate to afford N9-[(3-amino-2-methyl-4-
oxo-1,2,3,4-tetrahydroquinazolin-6-yl)sulfonyl]-2-(pyrazin-
2-yloxy)acetohydrazide 53. Compound 53 was then
reacted with various substituted aryl sulphonyl chlorides
to give the titled compounds 54–63. The structures of the
compounds were confirmed on the basis of elemental
and spectral data (Table 4). In the IR spectra of 51, the NH-
stretching band was clearly observed at 3200–3500 cm– 1
and not the bands for NH2 of the reactant. The –OH
stretching band was observed at 3390 cm– 1. This, again,
was absent in compound 53 because of the cyclization of
52. The peaks of NH2 and CH3 were observed at 3226 and
3235 cm– 1, respectively, in compound 53, and in com-
pounds 54–63 the NH2 stretching band was absent due to
substitution of the substituted aryl sulphonyl group. In
the NMR spectra of 55, d = 2.0 ppm and be attributed to
Antimycobacterial activity
The MIC values of the test compounds are summarized in
Table 5. For the comparison of the MIC values, the inter-
mediate compounds are also included in Table 5. The
results revealed that the MIC values of compounds 2–20
are lower than the MIC values of compounds 21–39. This
proves the importance of the azetidine ring for impart-
ing antimycobacterial activity to a compound. 28 and 37
show the best antimycobacterial activity of this class of
compounds. The activity may be due to the presence of
more electronegative groups like fluorine and methoxy.
These groups also impart lipophilicity to a compound.
The MIC values of 42–51 show promising antibacterial
activity in some of the compounds. 43 and 51 showed
good antimycobacterial activity. Again, the activity may
be due to the presence of a fluorine on the aromatic ring.
The literature survey revealed the importance of the pyri-
dine ring in imparting biological activity. The com-
pounds containing a pyridine ring show maximum anti-
mycobacterial activity. The fact that compounds 54–63
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

232
C. G. Bonde et al.
Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Table 5. In-vitro antimycobacterial activity of the test com-
pounds.
ian 300 MHz instrument at RSIC (Regional Sophisticated Instru-
mentation Centre), IIT (Indian Institute of Technology), Powai,
Mumbai, India. Elemental analyses were carried out using
FLASH EA 1112 CHN analyzer from Thermo Finnigen, Italy. Mass
spectra (FAB-MS) were recorded on 70 eV on Jeol D-300 spectro-
meter (Jeol Ltd., Tokyo, Japan).
Compound
Antimyco-
bacterial
Compound
Antimyco-
bacterial
Activitya)
Activitya) (MIC)
2
3
4
5
6
7
8
9
176
150
A250
165
124
174
140
115
NA
A250
138
192
177
123
155
127
A250
NA
163
41
78
49
23
19
25
12
3
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
19
35
17
26
89
47
7
25
23
A250
A250
100
1
28
79
NA
NA
NA
3
Synthesis of compounds 2–20
To a solution of 1 (0.01 mol) in ethanol (50 mL), sodium acetate
(0.01 mol) and various aromatic aldehydes (0.02 mol) were added
and the reaction mixture was heated under reflux for 6 h. Excess
of solvent was removed under vacuum. The residue so obtained
was washed with diethyl ether and recrystallized from metha-
nol. Using the same procedure, 19 different compounds were
synthesized.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Std. 1b)
Std. 2c)
Compound 2
Rf: 0.61 (acetonitrile/methanol, 1:1); IR: 3222 (NH), 1720 (C=O
stretching), 1660 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.20 (m, 1H, -N=CH-), 4.83 (s, 2H, OCH2), 7.15–7.62 (m, 3H, ArH),
7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 327
[M+ + 2], (100). Anal. calcd. for C13H10Cl2N4O2 (325.16): C, 48.02; H,
3.10; N, 17.23. Found: C, 48.10; H, 3.15; N, 17.26.
12
0.4
A250
A250
A250
A250
156
189
NA
23
25
32
A250
NA
Compound 3
Rf: 0.58 (acetonitrile/methanol, 1:1); IR: 3221 (NH), 1721 (C=O
stretching), 1655 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.21 (m, 1H, -N=CH-), 4.83 (s, 2H, OCH2), 7.10–7.66 (m, 3H, ArH),
7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 327
[M+ + 2] (100). Anal. calcd. for C13H10Cl2N4O2 (325.16): C, 48.02; H,
3.10; N, 17.23. Found: C, 48.10; H, 3.15; N, 17.26.
8
49
0.2
0.005
Compound 5
Rf: 0.48 (acetonitrile/methanol, 1:1); IR: 3219 (NH), 1722 (C=O
stretching), 1657 (N=C stretching) cm– 1;1H-NMR (CDCl3) d: 2.11–
2.21 (m, 1H, -N=CH-), 4.83 (s, 2H, OCH2), 7.35–7.70 (m, 4H, ArH),
7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H), FABMS (m/z, 100%): 276
[M+ + 2] (100). Anal. calcd. for C13H11FN4O2 (274): C, 56.93; H, 4.04;
N, 20.43. Found: C, 56.95; H, 4.06; N, 20.47.
a)
MIC: Minimum inhibitory concentration.
Std.1: Rifampin.
Std. 2: Isoniazid (INH); NA: not active at 500 lg/mL concentra-
tion; DMF has no antimycobacterial activity at the concentra-
tions used to dissolve the test compounds.?
b)
c)
Compound 6
did not show promising results may be due to their high
molecular weight.
Rf: 0.52 (acetonitrile/methanol, 1:1); IR: 3219 (NH), 1722 (C=O
stretching), 1657 (N=C stretching) cm– 1;1H-NMR (CDCl3) d: 2.11–
2.21 (m, 1H, -N=CH-), 4.83 (s, 2H, OCH2), 7.19–7.77 (m, 3H, ArH),
7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 382
[M+ + 2] (100). Anal. calcd. for C13H10BrN5O4 (380): C, 41.07; H, 2.65;
N, 18.42. Found: C, 41.00; H, 2.69; N, 18.44.
Experimental
General
Compound 8
Melting points were determined in open capillaries using the
microprocessor-based melting point apparatus, Model PMP-DM
(Veego Instruments, Corp., Mumbai, India) and are uncorrected.
Purity of the compounds was checked by precoated TLC plates
(E. Merck, Kieselgel 60 F25, Mumbai, India). IR spectra were
recorded using KBr pellets on Perkin-Elmer 337 spectrophotome-
ter from Perkin-Elmer International Incorporation, Rorkreuz,
Switzerland (mmax in cm– 1), 1H-NMR spectra were taken on a Var-
Rf: 0.41 (acetonitrile/methanol, 1:1); IR: 3222 (NH), 1720 (C=O
stretching), 1659 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.20 (m, 1H, -N=CH-), 3.73 (s, 3H, OCH3), 4.83 (s, 2H, OCH2), 7.15–
7.71 (m, 4H, ArH), 7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H),
8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS
(m/z, 100%): 288 [M+ + 2] (100). Anal. calcd. for C14H14N4O3 (286): C,
58.74; H, 4.93; N, 19.57. Found: C, 58.78; H, 4.97; N, 19.59.
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Activities of Substituted Pyrazine-Containing Analogues
233
Compound 10
Synthesis of compounds 21–39
Rf: 0.59 (acetonitrile/methanol, 1:1); IR: 3223 (NH), 1722 (C=O
stretching), 1653 (N=C stretching) cm– 1;1H-NMR (CDCl3) d: 2.12–
2.21 (m, 1H, -N=CH-), 3.73 (s, 6H, OCH3), 4.84 (s, 2H, OCH2), 7.22–
7.74 (m, 3H, ArH), 7.61 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H),
8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS
(m/z, 100%): 316 [M+] (100). Anal. calcd. for C15H16N4O4 (316.32): C,
56.96; H, 5.10; N, 17.71. Found: C, 56.99; H, 5.06; N, 17.74.
To a solution of compound 21–39 (0.01 mol) and TEA (12 mL) in
absolute alcohol (100 mL), chloroethyl acetate (0.02 mol) was
added dropwise with constant stirring over the period of 1 h.
After stirring for 1 h, the reaction mixture was refluxed for 2 h.
The reaction mixture was cooled and poured in ice-cold water.
The separated solid was filtered off, dried, and recrystallized
from petroleum ether (60–80). Using the same procedure, 19
such compounds were synthesized.
Compound 12
Rf: 0.74 (acetonitrile/methanol, 1:1); IR: 3219 (NH), 1722 (C=O
stretching), 1657 (N=C stretching) cm– 1;1H-NMR (CDCl3) d: 2.11–
2.21 (m, 1H, -N=CH-), 4.83 (s, 2H, OCH2), 7.29–7.81 (m, 4H, ArH),
7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 276
[M+ + 2] (100). Anal. calcd. for C13H11FN4O2 (274): C, 56.93; H, 4.04;
N, 20.43. Found: C, 56.97; H, 4.09; N, 20.45.
Compound 21
Rf: 0.35 (acetonitrile/methanol, 1:1); IR: 3229 (NH), 1720 (b-lac-
tum C=O), 1698 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.20–
2.33 (d, 1H, -CH-b-lactum), 2.36–2.40 (d, 1H, -b-lactum) , 4.82 (s,
2H, OCH2), 7.20–7.70 (m, 3H, ArH), 7.60 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 403.6 [M+ + 2] (100). Anal. calcd.
for C15H11Cl3N4O3 (401.6): C, 44.86; H, 2.76; N, 13.95. Found: C,
44.89; H, 2.78; N, 13.99.
Compound 14
Rf: 0.32 (acetonitrile/methanol, 1:1); IR: 3222 (NH), 1720 (C=O
stretching), 1659 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.20 (m, 1H, -N=CH-), 3.75 (s, 3H, OCH3), 4.83 (s, 2H, OCH2), 7.14–
7.75 (m, 4H, ArH), 7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H),
8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS
(m/z, 100%): 288 [M+ + 2] (100). Anal. calcd. for C14H14N4O3 (286): C,
58.74; H, 4.93; N, 19.57. Found: C, 58.78; H, 4.95; N, 19.59.
Compound 22
Rf: 0.46 (acetonitrile/methanol, 1:1); IR: 3228 (NH), 1721 (b-lac-
tum C=O), 1698 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.20 (d, 1H, -CH-b-lactum), 2.37–2.40 (d, 1H, -b-lactum), 4.82 (s,
2H, OCH2), 7.16–7.65 (m, 3H, ArH), 7.60 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 403.6 [M+ + 2] (100). Anal. calcd.
for C15H11Cl3N4O3 (401.6): C, 44.86; H, 2.76; N, 13.95. Found: C,
44.85; H, 2.75; N, 13.96.
Compound 15
Rf: 0.46 (acetonitrile/methanol, 1:1); IR: 3229 (NH), 1720 (C=O
stretching), 1663 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 2.11–
2.19 (m, 1H, -N=CH-), 4.82 (s, 2H, OCH2), 7.11–7.84 (m, 4H, ArH),
7.25 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 337
[M+ + 2] (100%). Anal. calcd. for C13H11BrN4O2 (335.16): C, 46.59; H,
3.31; N, 16.72. Found: C, 46.62; H, 3.33; N, 16.75.
Compound 24
Rf: 0.72 (acetonitrile/methanol, 1:1); IR: 3227 (NH), 1722 (b-lac-
tum C=O), 1699 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.20–
2.30 (d, 1H, -CH-b-lactum), 2.37–2.40 (d, 1H, -b-lactum), 4.82 (s,
2H, OCH2), 7.35–7.70 (m, 4H, ArH), 7.60 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 352.74 [M+ + 2] (100). Anal. calcd.
for C15H12ClFN4O3 (350.74): C, 51.37; H, 3.45; N, 15.97. Found: C,
51.39; H, 3.43; N, 16.01.
Compound 16
Rf: 0.52 (acetonitrile/methanol, 1:1); IR: 3229 (NH), 1720 (C=O
stretching), 1663 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 1.47
(d, 3H, CH3), 2.12–2.20 (m, 1H, -N=CH-), 4.82 (s, 2H, OCH2), 7.20–
7.62 (m, 4H, ArH), 7.25 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H),
8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS
(m/z, 100%): 272 [M+ + 2] (100). Anal. calcd. for C14H14N4O2 (270): C,
62.21; H, 5.22; N, 20.73. Found: C, 62.19; H, 5.25; N, 20.76.
Compound 25
Rf: 0.59 (acetonitrile/methanol, 1:1); IR: 3229 (NH), 1725 (b-lac-
tum C=O), 1697 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.21–
2.29 (d, 1H, -CH-b-lactum), 2.37–2.41 (d, 1H, -b-lactum), 4.82 (s,
2H, OCH2), 7.19–7.77 (m, 3H, ArH), 7.60 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H), FABMS (m/z, 100%): 458.64 [M+ + 2] (100). Anal. calcd.
for C15H11BrClN5O5 (456.64): C, 39.45; H, 2.43; N, 16.34. Found: C,
39.48; H, 2.49; N, 15.36.
Compound 18
Rf: 0.39 (acetonitrile/methanol, 1:1); IR: 3219 (NH), 1721 (C=O
stretching), 1656 (N=C stretching) cm– 1;1H-NMR (CDCl3) d: 2.11–
2.21 (m, 1H, -N=CH-), 4.83 (s, 2H, OCH2), 7.20–7.68 (m, 4H, ArH),
7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyra-
zine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 276
[M+ + 2] (100). Anal. calcd. for C13H14FN4O2 (274): C, 56.93; H, 4.04;
N, 20.43. Found: C, 56.90; H, 4.06; N, 20.40.
Compound 27
Compound 20
Rf: 0.49 (acetonitrile/methanol, 1:1); IR: 3227 (NH), 1721 (b-lac-
tum C=O), 1697 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.20–
2.33 (d, 1H, -CH-b-lactum), 2.36–2.40 (d, 1H, -b-lactum), 3.73 (s,
3H, OCH3), 4.82 (s, 2H, OCH2), 7.15–7.71 (m, 4H, ArH), 7.60 (s, 1H,
CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 365 [M+ + 2] (100).
Anal. calcd. for C16H15ClN4O4 (362.78): C, 52.97; H, 4.17; N, 15.44.
Found: C, 52.90; H, 4.20; N, 15.48.
Rf: 0.91 (acetonitrile/methanol, 1:1); IR: 3222 (NH), 1720 (C=O
stretching), 1659 (N=C stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.20 (m, 1H, -N=CH-), 3.71 (s, 3H, OCH3), 4.83 (s, 2H, OCH2), 7.21–
7.63 (m, 4H, ArH), 7.60 (s, 1H, CONH), 8.73 (t, 1H, pyrazine C5-H),
8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS
(m/z, 100%): 288 [M+ + 2] (100). Anal. calcd. for C14H14N4O3 (286): C,
58.74; H, 4.93; N, 19.57. Found: C, 58.77; H, 4.91; N, 19.55.
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

234
C. G. Bonde et al.
Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Compound 28
Compound 36
Rf: 0.64 (acetonitrile/methanol, 1:1); IR: 3227 (NH), 1721 (b-lac-
tum C=O), 1697 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.20–
2.33 (d, 1H, -CH-b-lactum), 2.36–2.40 (d, 1H, -b-lactum), 3.71 (s,
9H, OCH3), 4.82 (s, 2H, OCH2), 7.44–7.71 (m, 2H, ArH), 7.60 (s, 1H,
CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 425 [M+ + 2] (100).
Anal. calcd. for C16H19ClN4O6 (422.83): C, 51.30; H, 4.53; N, 13.25.
Found: C, 51.15; H, 4.55; N, 13.28.
Rf: 0.65 (acetonitrile/methanol, 1:1); IR: 3230 (NH), 1729 (b-lac-
tum C=O), 1699 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.11–
2.23 (d, 1H, -CH-b-lactum), 2.33–2.38 (d, 1H, -b-lactum), 4.83 (s,
2H, OCH2), 7.20–7.70 (m, 4H, ArH), 7.71 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 369 [M+ + 2] (100). Anal. calcd. for
C15H12Cl2N4O3 (367.19): C, 49.07; H, 3.29; N, 15.26. Found: C,
49.15; H, 3.37; N, 15.29.
Compound 37
Compound 29
Rf: 0.43 (acetonitrile/methanol, 1:1); IR: 3229 (NH), 1721 (b-lac-
tum C=O), 1699 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.21–
2.29 (d, 1H, -CH-b-lactum), 2.37–2.40 (d, 1H, -b-lactum), 4.82 (s,
2H, OCH2), 7.20–7.68 (m, 4H, ArH), 7.60 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 353 [M+ + 2] (100). Anal. calcd. for
C15H12ClFN4O3 (350.74): C, 51.37; H, 3.45; N, 15.97. Found: C,
51.41; H, 3.46; N, 15.95.
Rf: 0.26 (acetonitrile/methanol, 1:1); IR: 3225 (NH), 1725 (b-lac-
tum C=O), 1693 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.10–
2.21 (d, 1H, -CH-b-lactum), 2.32–2.36 (d, 1H, -b-lactum), 4.83 (s,
2H, OCH2), 7.22–7.74 (m, 3H, ArH), 7.65 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 395 [M+] (100). Anal. calcd. for
C17H17ClN4O6 (392.80): C, 51.98; H, 4.36; N, 14.26. Found: C, 52.00;
H, 4.31; N, 14.30.
Compound 39
Compound 30
Rf: 0.55 (acetonitrile/methanol, 1:1); IR: 3227 (NH), 1721 (b-lac-
tum C=O), 1697 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.20–
2.33 (d, 1H, -CH-b-lactum), 2.36–2.40 (d, 1H, -b-lactum), 3.73 (s,
3H, OCH3), 4.82 (s, 2H, OCH2), 7.15–7.71 (m, 4H, ArH), 7.60 (s, 1H,
CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 365 [M+ + 2] (100).
Anal. calcd. for C16H15ClN4O4 (362.78): C, 52.97; H, 4.17; N, 15.44.
Found: C, 52.91; H, 4.19; N, 15.48.
Rf: 0.26 (acetonitrile/methanol, 1:1); IR: 3230 (NH), 1729 (b-lac-
tum C=O), 1699 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.11–
2.23 (d, 1H, -CH-b-lactum), 2.33–2.38 (d, 1H, -b-lactum), 4.83 (s,
2H, OCH2), 7.20–7.70 (m, 4H, ArH), 7.71 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 369 [M+ + 2] (100). Anal. calcd. for
C15H12Cl2N4O3 (367.19): C, 49.07; H, 3.29; N, 15.26. Found: C,
49.10; H, 3.21; N, 15.29.
Synthesis of compound 40
Compound 31
A mixture of the thiosemicarbazide (0.01 mol), carbon disul-
phide (0.01 mol), and potassium hydroxide (0.1 mol) in ethanol
(50 mL) was heated under reflux for 5 h. The mixture was cooled
to separate the products. The product was recrystallized from
hydro-alcohol.
Rf: 0.55 (acetonitrile/methanol, 1:1); IR: 3229 (NH), 1721 (b-lac-
tum C=O), 1699 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.21–
2.29 (d, 1H, -CH-b-lactum), 2.37–2.40 (d, 1H, -b-lactum), 4.82 (s,
2H, OCH2), 7.29–7.81 (m, 4H, ArH), 7.60 (s, 1H, CONH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 353 [M+ + 2] (100). Anal. calcd. for
C15H12ClFN4O3 (350.74): C, 51.37; H, 3.45; N, 15.97. Found: C,
51.40; H, 3.49; N, 15.99.
Synthesis of compound 41
A mixture of 40 (3.75 g, 0.02 mol) and 85% hydrazine hydrate
(4.12 mL, 0.08 mol) in ethanol (40 mL) was refluxed for 12 h. The
excess solvent was removed under reduced pressure. The sepa-
rated solid crystals were filtered, washed with cold water, dried,
and recrystallized from absolute alcohol.
Compound 33
Rf: 0.57 (acetonitrile/methanol, 1:1); IR: 3227 (NH), 1721 (b-lac-
tum C=O), 1697 (C=O stretching) cm– 1; 1H-NMR (CDCl3) d: 2.20–
2.33 (d, 1H, -CH-b-lactum), 2.36–2.40 (d, 1H, -b-lactum), 3.73 (s,
3H, OCH3), 4.82 (s, 2H, OCH2), 7.14–7.75 (m, 4H, ArH), 7.60 (s, 1H,
CONH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 365 [M+ + 2] (100).
Anal. calcd. for C16H15ClN4O4 (362.78): C, 52.97; H, 4.17; N, 15.44.
Found: C, 53.05; H, 4.19; N, 15.46.
Rf: 0.44 (acetonitrile/methanol, 1:1); IR: 3335, 3269 (NH-
stretching), 1494, 1467, 1420 (triazole) cm– 1; H-NMR (CDCl3) d:
1
2.11–2.19 (m, 1H, -N=CH-), 4.80 (s, 2H, OCH2), 5.81 (s, 2H, NH2),
8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d,
1H, pyrazine C2-H), 13.39 (s, 1H, SH); FABMS (m/z, 100%): 224 [M+]
(100). Anal. calcd. for C7H8N6OS (224.25): C, 37.49; H, 3.60; N,
37.48. Found: C, 37.52; H, 3.56; N, 37.52.
Compound 34
Synthesis of compounds 42–51
Rf: 0.78 (acetonitrile/methanol, 1:1); IR: 3230 (NH), 1729 (3.1.2.11
A mixture of 41 (0.02 mol) and an aromatic acid (0.02 mol) in
POCl3 (40 mL) was refluxed for 7 h. The reaction mixture was
gradually poured onto crushed ice by stirring and potassium car-
bonate was added to the mixture by stirring. An appropriate
amount of potassium hydroxide was added to reach pH 8 and
the mixture was left to stand overnight. The solid which then
separated was filtered, washed with cold water, dried, and
recrystallized from absolute alcohol to get the final products.
b-lactum C=O), 1699 (C=O stretching) cm– 1; H-NMR (CDCl3) d:
1
2.11–2.23 (d, 1H, -CH-b-lactum), 2.33–2.38 (d, 1H, -b-lactum),
4.83 (s, 2H, OCH2), 7.11–7.84 (m, 4H, ArH), 7.71 (s, 1H, CONH),
8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d,
1H, pyrazine C2-H), FABMS (m/z, 100%): 413.5 [M+ + 2] (100). Anal.
calcd.for C15H12BrClN4O3 (411.64): C, 43.80; H, 2.95; N, 13.63.
Found: C, 43.77; H, 2.94; N, 13.61.
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
Activities of Substituted Pyrazine-Containing Analogues
235
Rf: 0.58 (acetonitrile/methanol, 1:1); IR: 3390 (OH-stretching),
1680, 1733 (C=O stretching), 3226, 3235 (NH-stretching) cm– 1
Compound 42
;
Rf: 0.66 (acetonitrile/methanol, 1:1); IR: 1626 (C=N stretching),
1266 (N-N=C), 694 (C-S-C) cm– 1; 1H-NMR (CDCl3) d: 7.39–7.81 (m,
4H, ArH),8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 346 [M+ + 1] (100).
Anal. calcd. for C14H9ClN6OS (344.78): C, 48.77; H, 2.63; N, 24.37.
Found: C, 48.81; H, 2.68; N, 24.46.
1H-NMR (CDCl3) d: 2.00 (s, 2H, 2 NH), 4.83 (s, 2H, OCH2), 7.80–8.70
(m, 3H, ArH), 8.00 (s, 1H, NH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d,
1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H), 11.00 (s, 1H, OH);
FABMS (m/z, 100%): 367 [M+] (100). Anal. calcd. for C13H13N5O6S
(367.34): C, 42.51; H, 3.57; N, 19.06. Found: C, 42.55; H, 3.61; N,
19.10.
Compound 43
Rf: 0.62 (acetonitrile/methanol, 1:1); IR: 1627 (C=N stretching),
1268 (N-N=C), 695 (C-S-C) cm– 1; 1H-NMR (CDCl3) d: 7.21–7.72 (m,
4H, ArH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 330 [M+ + 2] (100).
Anal. calcd. for C14H9FN6OS (328.33): C, 51.22; H, 2.76; N, 25.60.
Found: C, 51.27; H, 2.78; N, 25.57.
Synthesis of compound 53
A mixture of 52 and hydrazine hydrate in ethanol was refluxed
on a water bath for 3 h. The content was cooled and poured onto
crushed ice, filtered, and washed with water. The isolated prod-
uct was recrystallized from ethanol.
Rf: 0.63 (acetonitrile/methanol, 1:1); IR: 3390 (OH-stretching),
3226, 3235 (NH-stretching), 1680, 1675 (C=O stretching), 1160
(S=O stretching) cm– 1;1H-NMR (CDCl3) d: 1.47 (d, 3H, CH3), 2.00 (s,
1H, NH), 3.13 (s, 2H, NH2), 4.00 (s, 1H, NH of quinazolinone), 4.83
(s, 2H, OCH2), 4.90 (q, 1H, CH), 6.90–8.10 (m, 3H, ArH), 8.00 (s, 1H,
NH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21
(d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 367 [M+] (100). Anal.
calcd. for C14H16N8O5S (408.40): C, 41.17; H, 3.95; N, 27.44. Found:
C, 41.21; H, 3.97; N, 27.48.
Compound 45
Rf: 0.80 (acetonitrile/methanol, 1:1); IR: 1628 (C=N stretching),
1263 (N-N=C), 692 (C-S-C) cm– 1; 1H-NMR (CDCl3) d: 7.29–7.79 (m,
3H, ArH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 400 [M+] (100).
Anal. calcd. for C14H9ClN6OS (400.33): C, 42.00; H, 2.01; N, 27.99.
Found: C, 42.04; H, 2.06; N, 28.05.
Compound 46
Synthesis of compounds 54–63
Rf: 0.63 (acetonitrile/methanol, 1:1); IR: 1627 (C=N stretching),
1261 (N-N=C), 691 (C-S-C) cm– 1; 1H-NMR (CDCl3) d: 7.21–7.71 (m,
3H, ArH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 325 [M+ + 1] (100).
Anal. calcd. for C14H8N8O5S (324.37): C, 55.54; H, 3.73; N, 25.91.
Found: C, 55.52; H, 3.75; N, 25.86.
A mixture of 53 and substituted aryl sulphonyl chloride (0.01
mol), in ethanol (25 mL) and pyridine (1 mL) was refluxed in an
oil bath at 1208C for 4 h. The reaction mixture was cooled and
poured in crushed ice, filtered and washed with water. The prod-
uct was recrystallized from ethanol.
Compound 47
Compound 55
Rf: 0.57 (acetonitrile/methanol, 1:1); IR: 1615 (C=N stretching),
1263 (N-N=C), 691 (C-S-C) cm– 1; 1H-NMR (CDCl3) d: 7.25–7.78 (m,
5H, ArH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H),
9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 311 [M+ + 1] (100).
Anal. calcd. for C14H10N6OS (310.34): C, 54.18; H, 3.25; N, 27.08.
Found: C, 54.24; H, 3.27; N, 27.19.
Rf: 0.47 (acetonitrile/methanol, 1:1); IR: 3390 (OH-stretching),
3224, 3218 (NH-stretching), 1720, 1675 (C=O stretching), 1166
(S=O stretching) cm– 1; 1H-NMR (CDCl3) d: 1.47 (d, 3H, CH3), 2.00 (s,
2H, NH2), 4.00 (s, 1H, NH of quinazolinone), 4.83 (s, 2H, OCH2),
4.90 (q, 1H, CH), 6.90–8.40, (m, 7H, ArH), 8.00 (s, 1H, NH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 585 [M+ + 2] (100). Anal. calcd. for
C20H19ClN8O7S2 (583.00): C, 41.20; H, 3.28; N, 19.22. Found: C,
41.24; H, 3.30; N, 19.26.
Compound 48
Rf: 0.75 (acetonitrile/methanol, 1:1); IR: 1629 (C=N stretching),
1261 (N-N=C), 689 (C-S-C) cm– 1 1H-NMR (CDCl3) d: 2.71 (s, 2H,
;
CH2), 7.10–7.82 (m, 5H, ArH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d,
1H, pyrazine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z,
100%): 325 [M+ + 1] (100). Anal. calcd. for C15H12N6OS (324.37): C,
55.54; H, 3.73; N, 25.91. Found: C, 55.59; H, 3.75; N, 25.82.
Compound 56
Rf: 0.52 (acetonitrile/methanol, 1:1); IR: 3391 (OH-stretching),
3225, 3219 (NH-stretching), 1721, 1676 (C=O stretching), 1165
(S=O stretching) cm– 1;1H-NMR (CDCl3) d: 1.47 (d, 3H, CH3), 2.00 (s,
2H, NH2), 4.00 (s, 1H, NH of quinazolinone), 4.83 (s, 2H, OCH2),
4.90 (q, 1H, CH), 6.96–8.20 (m, 7H, ArH), 8.00 (s, 1H, NH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 594 [M+] (100). Anal. calcd. for
C20H19N9O9S2 (593.56): C, 40.47; H, 3.23; N, 21.24. Found: C, 40.54;
H, 3.26; N, 21.19.
Compound 49
Rf: 0.46 (acetonitrile/methanol, 1:1); IR: 1629 (C=N stretching),
1226 (furan C-O-C), 694 (C-S-C) cm– 1; 1H-NMR (CDCl3) d: 7.45–8.13
(m, 3H, furan), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine
C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 300 [M+]
(100). Anal. calcd. for C12H8N6O2S (300.30): C, 48.00; H, 2.69; N,
27.99. Found: C, 48.05; H, 2.66; N, 27.95.
Compound 57
Synthesis of compound 52
Rf: 0.71 (acetonitrile/methanol, 1:1); IR: 3389 (OH-stretching),
3225, 3219 (NH-stretching), 1722, 1676 (C=O stretching), 1168
(S=O stretching) cm– 1; 1H-NMR (CDCl3) d: 1.47 (d, 3H, CH3), 2.00 (s,
2H, NH2), 4.00 (s, 1H, NH of quinazolinone), 4.83 (s, 2H, OCH2),
4.90 (q, 1H, CH), 6.95–8.25, (m, 7H, ArH), 8.00 (s, 1H, NH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.20 (s, 1H,
A mixture of 3 and 2-(acetylamino)-5-(chlorosulfonyl)benzoic
acid (0.01 mol), in ethanol (25 mL) and pyridine (1 mL) was
refluxed in an oil bath at 1208C for 4 h. The reaction mixture
was cooled and poured into crushed ice, filtered, and washed
with water. The product was recrystallized from ethanol.
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com

236
C. G. Bonde et al.
Arch. Pharm. Chem. Life Sci. 2010, 343, 228–236
C6H4OH), 9.21 (d, 1H, pyrazine C2-H), FABMS (m/z, 100%): 565 [M+]
(100). Anal. calcd. for C20H20N8O8S2 (564.56): C, 42.55; H, 3.57; N,
19.85. Found: C, 42.41; H, 3.59; N, 19.79.
0.5% sterilized horse serum for antimycobacterial activity.
Rifampcin and isoniazid (INH) were used as reference standard
for antimycobacterial activity. The stock solution (2–4 lg/mL) of
test compounds was prepared in a mixture of sterile water and
dimethylformamide (8:2) solvent. The stock solution was steri-
lized by passage through 0.2 mm polycarbonate sterile mem-
brane filters (Nuclepore). Further, the serial dilution of the test
compounds was carried out and the following concentration
was used: 1000, 500, 250, 125, 62, 32, 16, 8, 4, and 1 g/mL. Test
compounds at various concentrations were added to the culture
medium in a sterilized borosilicate test tube and the H37 Rv
strain of mycobacterium tuberculosis was inoculated at 106
bacilli/mL concentration. The tubes were incubated at 378C for
14 days for antimycobacterial activity and then examined for
the presence or absence of growth of the test organisms. All
experiments were performed in triplicate. The MIC values were
obtained from the lowest concentration of the test compound
where the tubes remained clear, indicating that the bacterial
growth was completely inhibited at this concentration. The MIC
values were expressed in lg/mL and the results are shown in
Table 5.
Compound 59
Rf: 0.77 (acetonitrile/methanol, 1:1); IR: 3391 (OH-stretching),
3225, 3215 (NH-stretching), 1722, 1676 (C=O stretching), 1164
(S=O stretching) cm– 1; 1H-NMR (CDCl3) d: 1.26 (t, 6H, OCH3-C6H4),
1.47 (d, 3H, CH3), 2.00 (s, 2H, NH2), 4.00 (s, 1H, NH of quinazoli-
none), 4.83 (s, 2H, OCH2), 4.90 (q, 1H, CH), 6.90–8.40, (m, 6H,
ArH), 8.00 (s, 1H, NH), 8.73 (t, 1H, pyrazine C5-H), 8.82 (d, 1H, pyr-
azine C6-H), 9.21 (d, 1H, pyrazine C2-H); FABMS (m/z, 100%): 609
[M+] (100). Anal. calcd. for C22H24N8O9S2 (608.61): C, 43.42; H, 3.97;
N, 18.41. Found: C, 43.46; H, 3.96; N, 18.37.
Compound 61
Rf: 0.45 (acetonitrile/methanol, 1:1); IR: 3392 (OH-stretching),
3225, 3214 (NH-stretching), 1721, 1674 (C=O stretching), 1165
(S=O stretching) cm– 1;1H-NMR (CDCl3) d: 1.47 (d, 3H, CH3), 2.00 (s,
2H, NH2), 4.00 (s, 1H, NH of quinazolinone), 4.83 (s, 2H, OCH2),
4.90 (q, 1H, CH), 7.10–8.40 (m, 7H, ArH), 8.00 (s, 1H, NH), 8.73 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 566 [M+] (100%). Anal. calcd. for
C20H19FN8O7S2 (566.55): C, 42.40; H, 3.38; N, 19.78. Found: C,
42.51; H, 3.41; N, 19.81.
The authors have declared no conflict of interest.
References
Compound 63
Rf: 0.59 (acetonitrile/methanol, 1:1); IR: 3386 (OH-stretching),
3231, 3211 (NH-stretching), 1714, 1672 (C=O stretching), 1162
(S=O stretching) cm– 1; 1H-NMR (CDCl3) d: 1.46 (d, 3H, CH3), 2.10 (s,
2H, NH2), 3.90 (s, 1H, NH of quinazolinone), 4.76 (s, 2H, OCH2),
5.01 (q, 1H, CH), 7.20–8.20 (m, 6H, ArH), 8.10 (s, 1H, NH), 8.75 (t,
1H, pyrazine C5-H), 8.82 (d, 1H, pyrazine C6-H), 9.21 (d, 1H, pyra-
zine C2-H); FABMS (m/z, 100%): 630 [M+ + 2] (100). Anal. calcd. for
C20H18ClN9O9S2 (628.00): C, 38.25; H, 2.89; N, 20.07. Found: C,
38.28; H, 2.92; N, 20.11.
[1] World Health Organization, Tuberculosis 2007, Fact Sheet
No. 104.
[2] K. A. El Sayed, P. Bartyzel, X. Y. Shen, T. L. Perry, et al.,
Tetrahedron 2000, 56, 949–953.
[3] H. Tomioka, K. Namba, Kekkaku 2006, 81, 753–774.
[4] E. L. Corbett, C. J. Watt, N. Walker, D. Maher, et al., Arch.
Intern. Med. 2003, 163, 1009–1021.
[5] M. A. Espinal, Tuberculosis 2003, 83, 44–51.
Antimycobacterial activity
[6] R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 2001,
163, 1055–1058.
All the tested compounds were assayed in vitro for antimycobac-
terial activity against the H37 Rv strain of M. tuberculosis strain
using a standard protocol [16]. The minimum inhibitory concen-
tration (MIC) was determined by the test-tube dilution technique
using Mueller-Hinton nutrient broth (for antibacterial) and
modified Kirchner's culture medium containing 0.5% sterilized
horse serum for antimycobacterial activity. The MIC values were
also tested for rifampin and isoniazid (INH). As this class of com-
pounds has a similarity with pyrazinamide, yet pyrazinamide is
a prodrug, it does not give the antimycobacterial activity in vitro,
so INH is used. Although rifampin does not have a structural
similarity with the synthesized analogues, it contains the piperi-
dine ring and it inhibits DNA-dependent RNA polymerase in bac-
terial cells by binding its beta-subunit and showed the very good
antimycoacterial activity in vitro. Therefore, for comparison
with the most potent existing drug, rifampin is used as one of
the standards.
[7] C. G. Bonde, B. A. Nadkarni, B. G. Khadse, Indian J. Hetero-
cycl. Chem. 2001, 10, 271–274.
[8] S. P. Singh, S. S. Parmar, K. Raman, V. I. Stenherb, Chem.
Pharm. Bull. 1981, 81, 197.
[9] P. B. Patel, J. T. Trivedi, Ind. Chem. Soc. 1987, 54, 765.
[10] M. V. Diurno, O. Mazzoni, E. Piscopo, A. Caligmano, A.
Bolognese, J. Med. Chem. 1992, 35, 2910–2912.
[11] A. M. Omar, N. H. Eshba, J. Pharm. Sci. 1984, 73, 1166–
1168.
[12] M. Chaudhary, S. S. Parmar, S. K. Chaudhari, B. V. Ramasas-
try, J. Pharm. Sci. 1976, 65, 443–446.
[13] F. A. Ragab, M. M. Hussein, M. Hanna, G. S. Hassan, J.
Pharm. Sci. 1993, 34, 387–400.
[14] C. G. Bonde, N. J. Gaikwad, Bioorg. Med. Chem. 2004, 12,
2151–2161.
[15] C. G. Bonde, S. I. Rane, N. J. Gaikwad, Current. Pharm. Res. J.
2007, 1, 31–36.
Microbiology
All the test compounds were assayed in vitro for antimycobacte-
rial activity and evaluated against the H37Rv strain of M. tubercu-
losis. The MIC was determined by the test tube dilution tech-
nique using modified Kirchner's culture medium containing
[16] D. F. Sahm, J. A. Washington, A. Ballows, W. Housler, et al.,
A Manual of Clinical Microbiology, 5th Ed., ASM, Washington,
DC, 1991, p. 1105.
i 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.archpharm.com